TY  - JOUR
AU  - Ortiz, Raúl
AU  - Perazzoli, Gloria
AU  - Cabeza, Laura
AU  - Jiménez-Luna, Cristina
AU  - Luque, Raquel
AU  - Prados, Jose
AU  - Melguizo, Consolación
PY  - 2021
DO  - 10.2174/1570159X18666200626204005
UR  - http://hdl.handle.net/10668/15832
T2  - Current neuropharmacology
AB  - Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine), is frequently used together with radiotherapy as part of the first-line treatment of high-grade gliomas. The...
LA  - en
KW  - Alkylating agents
KW  - cancer
KW  - chemotherapy
KW  - clinical trials
KW  - drug resistance
KW  - nanoparticles
KW  - Antineoplastic Agents, Alkylating
KW  - Brain Neoplasms
KW  - Cell Line, Tumor
KW  - Humans
KW  - Nanotechnology
KW  - Temozolomide
TI  - Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications.
TY  - research article
VL  - 19
ER  -